## Azlan Husin

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7611798/publications.pdf

Version: 2024-02-01

933410 940516 43 277 10 16 citations h-index g-index papers 43 43 43 450 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients—Frequency and clinical outcome. Leukemia Research, 2014, 38, 454-459.	0.8	44
2	<i>HOXA4</i> Gene Promoter Hypermethylation as an Epigenetic Mechanism Mediating Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients. BioMed Research International, 2013, 2013, 1-7.	1.9	24
3	Risk Factors of Candida parapsilosis Catheter-Related Bloodstream Infection. Frontiers in Public Health, 2021, 9, 631865.	2.7	23
4	Fatal septicemic shock associated with Strongyloides stercoralis infection in a patient with angioimmunoblastic T-cell lymphoma: A case report and literature review. Parasitology International, 2012, 61, 508-511.	1.3	21
5	Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia. Oncology and Therapy, 2016, 4, 303-314.	2.6	18
6	Clinical impact of <i>ABCC1</i> and <i>ABCC2</i> genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 685-690.	1.5	15
7	DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas. Pathology, 2017, 49, 731-739.	0.6	15
8	Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP. Experimental and Molecular Pathology, 2015, 99, 537-545.	2.1	13
9	Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients. Journal of Genetics, 2018, 97, 835-842.	0.7	13
10	Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients. Hematology Reports, 2012, 4, e23.	0.8	11
11	Characterisation and Clinical Significance of FLT3-ITD and non-ITD in Acute Myeloid Leukaemia Patients in Kelantan, Northeast Peninsular Malaysia. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4869-4872.	1.2	11
12	Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patients. Journal of Genetics, 2017, 96, 633-639.	0.7	9
13	Autologous Peripheral Blood Stem Cell Transplantation Among Lymphoproliferative Disease Patients: Factors Influencing Engraftment. Oman Medical Journal, 2019, 34, 34-43.	1.0	7
14	Guidelines for nucleic acid detection and analysis in hematological disorders. Malaysian Journal of Pathology, 2015, 37, 165-73.	0.2	7
15	Genetic variations in influx transporter gene are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients. Journal of Genetics, 2018, 97, 835-842.	0.7	7
16	Survival and prognostic factors in Malaysian acute myeloid leukemia patients after allogeneic haematopoietic stem cell transplantation. International Journal of Hematology, 2013, 98, 197-205.	1.6	6
17	Low Level of TERC Gene Amplification between Chronic Myeloid Leukaemia Patients Resistant and Respond to Imatinib Mesylate Treatment. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1863-1869.	1.2	6
18	Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndrome. The Cochrane Library, 0, , .	2.8	4

#	Article	IF	Citations
19	Left atrial appendage and atrial septal occlusion in elderly patients with atrial septal defect and atrial fibrillation. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1252-1257.	1.2	4
20	Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN). International Journal of Environmental Research and Public Health, 2021, 18, 7582.	2.6	4
21	Design of InnoPrimers-Duplex Real-Time PCR for Detection and Treatment Response Prediction of EBV-Associated Nasopharyngeal Carcinoma Circulating Genetic Biomarker. Diagnostics, 2021, 11, 1761.	2.6	4
22	A review of AML classification: a single institution experience in a developing country. Journal of Hematopathology, 2014, 7, 3-8.	0.4	3
23	Conformation sensitive gel electrophoresis for the detection of calreticulin mutations in BCRâ€ABL1â€negative myeloproliferative neoplasms. International Journal of Laboratory Hematology, 2021, 43, 1451-1457.	1.3	2
24	Aberrant Methylation of Tumour Suppressor Gene ADAM12 in Chronic Lympocytic Leukemia Patients: Application of Methylation Specific-PCR Technique. Asian Pacific Journal of Cancer Prevention, 2021, 22, 85-91.	1.2	2
25	Green Technology Wrist Band with Patient Identification Near Field Communication (NFC) or Radio Frequency Identification (RFID) Security Features. Advanced Science Letters, 2017, 23, 5329-5332.	0.2	2
26	Characterizing PML/RAR? Isoforms of Acute Promyelocytic Leukemia (APL) in Malay Patients. Bangladesh Journal of Medical Science, 2014, 13, 311-315.	0.2	1
27	Risk Factors for PoorAutologous Peripheral blood Stem Cell Mobilization among Lymphoproliferative Disease Patients. Bangladesh Journal of Medical Science, 2020, 19, 458-466.	0.2	1
28	Influence of CYP1A2, CYP3A5 and CYP2C19 Polymorphisms on Imatinib Mesylate Drug Responses in Three Major Asian Ethnic Groups and Variation of IM and Active Metabolite (M1) Trough Level Among Chronic Myeloid Leukemia Patients. Annals of Oncology, 2012, 23, xi133-xi134.	1.2	0
29	Thrombotic Thrombocytopenic Purpura: Three Peripartum Cases and Diagnostic Challenges. Clinical Medicine Insights: Case Reports, 2013, 6, CCRep.S12122.	0.7	0
30	P0172Clinical relevance of a pharmacogenetic approach using multiple transporter genes to predict response and resistance to imatinib therapy in Malaysian patients with chronic myeloid leukaemia. European Journal of Cancer, 2015, 51, e33.	2.8	0
31	Molecular genetic and epigenetic markers of Imatinib resistance in chronic myeloid leukemia patients. Annals of Oncology, 2016, 27, vii93.	1.2	0
32	Dyspnea on swallowing: a case of thyroid lymphoma. Bangladesh Journal of Medical Science, 2017, 16, 138-141.	0.2	0
33	Vascular Endothelial Growth Factor Receptor Polymorphisms and im Treatment Response in Chronic Myeloid Leukemia Patients. Annals of Oncology, 2019, 30, vi110-vi111.	1.2	0
34	Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients. Asian Pacific Journal of Cancer Prevention, 2021, 22, 565-571.	1.2	0
35	Integrating Molecular, Epigenetic and Pharmacogenetic Approaches in Managing Imatinib Resistance Among Malaysian Chronic Myeloid Leukemia Patients. Blood, 2014, 124, 3150-3150.	1.4	0
36	Leukemia Medical Application with Security Features. Journal of Software, 2015, 10, 577-598.	0.6	0

## Azlan Husin

#	Article	IF	CITATION
37	Placebo Controlled Trials: Interests of Subjects versus Interests of Drug Regulators. The Malaysian Journal of Medical Sciences, 2017, 24, 1-4.	0.5	0
38	Homonymous Hemianopia: A Rare Presentation of Secondary Central Nervous System Neurolymphomatosis. Cureus, 2018, 10, e2708.	0.5	0
39	Bartonella henselae Neuroretinitis: A Rare Coinfection in POEMS Syndrome. Türk Oftalmoloji Dergisi, 2020, 50, 371-376.	0.9	0
40	CYP3A4*18 and CYP3A5*3 Polymorphisms in Modulating Susceptibility Risk in Malaysian Chronic Myeloid Leukaemia Patients. Archives of Orofacial Sciences, 2020, 15, 23-33.	0.1	0
41	Relapsed/Progressive Disease and Its Prognostic Factors among Multiple Myeloma Patients Receiving Novel Agent Treatment in North East Peninsular Malaysia: A Single Centre Experience. The Malaysian Journal of Medical Sciences, 2020, 27, 62-77.	0.5	0
42	FACTORS INFLUENCING POST- CRYOPRESERVED CD34+ CELLS VIABILITY IN THE HARVESTED PRODUCTS OF AUTOLOGOUS HAEMATOPOIETIC STEM CELLS. Transfusion Clinique Et Biologique, 2022, , .	0.4	0
43	A case report of cold autoimmune haemolyticanaemia in pulmonary tuberculosis. Bangladesh Journal of Medical Science, 2022, 21, 754-757.	0.2	0